GCN2iB

Overview

GCN2iB is an ATP-competitive, selective GCN2 inhibitor with an IC 50 of 2.4 nM. GCN2iB inhibits the activation of the GCN2 pathway and upregulates GPX4 . GCN2iB enhances the anticancer effect of ASNase against acute lymphoblastic leukemia. GCN2iB increases left ventricular ejection fraction, while reducing fasting blood glucose and myocardial fibrosis. GCN2iB can be used in research related to acute lymphoblastic leukemia, acute myeloid leukemia and diabetic cardiomyopathy.

Application

Products | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Heart Disease | Products > Disease Areas > Blood Disease | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > Acute Myeloid Leukemia | Products > Disease Areas > Acute Lymphoblastic Leukemia | Products > Disease Areas > Cardiomyopathy | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Metabolic Disease | Products > Research Areas > Cardiovascular Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Eukaryotic Initiation Factor (eIF) | Products > Signaling Pathways > Glutathione Peroxidase

Product Information

• Catalog No.: HY-112654
• CAS No.: 2183470-12-2
• Molecular Formula: C18H12ClF2N5O3S
• Molecular Weight: 451.83
• Purity: 99.83%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: ≥ 1.67 mg/mL (3.70 mM); Clear solution
• Availability: In-stock

Source

Original product source